Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.55 |
| ▸ | FOLH1 | Q04609 | 5/20 | 0.50 |
| ▸ | NOD1 | Q9Y239 | 5/20 | 0.46 |
| ▸ | GNPAT | O15228 | 1/20 | 0.43 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.42 |
| ▸ | NMT2 | O60551 | 1/20 | 0.41 |
| ▸ | NMT1 | P30419 | 1/20 | 0.41 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.38 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23695804 | 0.99 | SLC6A5 (0.57) | SLC6A5FOLH1NOD1GNPATC3AR1 | |
| SCHEMBL30634501 | 0.96 | SLC6A5 (0.53) | SLC6A5FOLH1NOD1GNPATC3AR1 | |
| SCHEMBL29072118 | 0.90 | NOD1 (0.48) | SLC6A5FOLH1NOD1GNPATC3AR1 | |
| SCHEMBL29072117 | 0.90 | NOD1 (0.48) | SLC6A5FOLH1NOD1GNPATC3AR1 | |
| SCHEMBL24630046 | 0.90 | NOD1 (0.48) | SLC6A5FOLH1NOD1GNPATC3AR1 | |
| SCHEMBL29335571 | 0.89 | NOD1 (0.50) | SLC6A5FOLH1NOD1GNPATC3AR1 | |
| SCHEMBL17481432 | 0.86 | NOD1 (0.63) | SLC6A5NOD1 | |
| SCHEMBL22473457 | 0.86 | SLC6A5 (0.44) | SLC6A5FOLH1NMT2NMT1 | |
| SCHEMBL18089437 | 0.85 | NOD1 (0.66) | SLC6A5NOD1 | |
| SCHEMBL24630082 | 0.85 | NOD1 (0.43) | SLC6A5FOLH1NOD1GNPATC3AR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240066132-A1 | NOVEL FATTY ACIDS AND THEIR USE IN CONJUGATION TO BIOMOLECULES | NOVARTIS AG (CH) | 2024-02-29 | — | — | US | disclosed |
| US-11752211-B2 | Fatty acids and their use in conjugation to biomolecules | NOVARTIS AG (CH) | 2023-09-12 | — | — | US | disclosed |
| US-11066667-B2 | Organic compositions to treat APOC3-related diseases | Arrowhead Pharmaceuticals, Inc. (US) | 2021-07-20 | — | — | US | disclosed |
| US-20210000964-A1 | NOVEL FATTY ACIDS AND THEIR USE IN CONJUGATION TO BIOMOLECULES | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2021-01-07 | — | — | US | disclosed |
| EP-3736334-A1 | RNAI COMPOSITIONS TO TREAT APOC3-RELATED DISEASES | Arrowhead Pharmaceuticals, Inc. (US) | 2020-11-11 | — | — | EP | disclosed |
| US-20190233817-A1 | ORGANIC COMPOSITIONS TO TREAT APOC3-RELATED DISEASES | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2019-08-01 | — | — | US | disclosed |
| US-10240153-B2 | Organic compositions to treat APOC3-related diseases | Arrowhead Pharmaceuticals, Inc. (US) | 2019-03-26 | — | — | US | disclosed |
| US-20170137814-A1 | ORGANIC COMPOSITIONS TO TREAT APOC3-RELATED DISEASES | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2017-05-18 | — | — | US | disclosed |
| WO-2016011123-A1 | ORGANIC COMPOSITIONS TO TREAT APOC3-RELATED DISEASES | ARROWHEAD RESEARCH CORPORATION (US) | 2016-01-21 | — | — | WO | disclosed |
| WO-2015200078-A1 | FATTY ACIDS AND THEIR USE IN CONJUGATION TO BIOMOLECULES | NOVARTIS AG (CH) | 2015-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240066132-A1 | NOVEL FATTY ACIDS AND THEIR USE IN CONJUGATION TO BIOMOLECULES | FABP1, FABP2, FABP3 | SLC6A5 2254/4885FOLH1 1189/4885NOD1 1689/4885 |
| US-11752211-B2 | Fatty acids and their use in conjugation to biomolecules | FABP1, FABP2, FABP3 | SLC6A5 2405/4885FOLH1 1283/4885NOD1 1788/4885 |
| US-20170137814-A1 | ORGANIC COMPOSITIONS TO TREAT APOC3-RELATED DISEASES | APOL1, APOB, LDLR | SLC6A5 4474/4885FOLH1 3656/4885NOD1 2027/4885 |
| US-20190233817-A1 | ORGANIC COMPOSITIONS TO TREAT APOC3-RELATED DISEASES | APOL1, APOB, LDLR | SLC6A5 4474/4885FOLH1 3656/4885NOD1 2027/4885 |
| US-10240153-B2 | Organic compositions to treat APOC3-related diseases | APOL1, APOB, LDLR | SLC6A5 4474/4885FOLH1 3656/4885NOD1 2027/4885 |
| US-20210000964-A1 | NOVEL FATTY ACIDS AND THEIR USE IN CONJUGATION TO BIOMOLECULES | FABP1, FABP2, FABP3 | SLC6A5 2254/4885FOLH1 1189/4885NOD1 1689/4885 |
| US-11066667-B2 | Organic compositions to treat APOC3-related diseases | APOL1, APOB, LDLR | SLC6A5 4474/4885FOLH1 3656/4885NOD1 2027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.